News
Dr. Nathan Chen leaves OBI Pharma; Accepts New Role on Company’s Medical Advisory Board
OBI Pharma today announced that Dr. Nathan Chen has resigned …
2016-08-11
OBI Pharma Presents Data for Novel Investigational OBI-822/OBI-821 in Patients with Metastatic Breast Cancer at the 2016 American Society of Clinical Oncology Annual Meeting
Results from Phase II/III Clinical Trials Show Improvement in Subset …
2016-06-05
OBI’s Abstract at ASCO 2016: Randomized Phase 2/3 Trial of Active Immunotherapy With OPT-822/OPT-821 in Patients With Metastatic Breast Cancer
Background: Globo H is a glycolipid that is highly expressed …
2016-05-19
OBI Pharma to Present New Data at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
Oral Presentation Highlights the Results of a Phase II/III Trial …
2016-05-19
Company Position Statement Regarding Recent Investigation of Senior Executives
OBI Pharma strongly denies allegations of insider trading. Since March …
2016-05-13
OBI Pharma Announces Decision By ASCO to Accept its Abstract for Oral Presentation at ASCO’S 2016 Annual Meeting
OBI Pharma, Inc. today announced that the American Society of …
2016-03-31
OBI Pharma Reports Topline Results from OBI-822/821 Randomized Controlled Phase 2/3 Clinical Trial in Patients with Metastatic Breast Cancer
Plans to Advance to Global Phase 3 Clinical Program TAIPEI, …
2016-02-21
OBI Pharma Enters Exclusive Agreement with MSD for Rights to DIFICID® (fidaxomicin) in Taiwan
OBI Eligible to Receive Milestone Payments as well as US$3.0 …
2015-10-05